dorsaVi Expands Global Reach of ViMove+ Across Sport, Healthcare and Research
dorsaVi Limited (ASX: DVL) has announced further growth in the deployment of its ViMove+ motion analysis technology, with new collaborations and clinical programs supporting expansion across healthcare, elite sport and research markets.
The company’s Select Network has grown to more than 120 operational clinical sites, with additional locations currently being introduced across the United States. Integration of ViMove+ into the Select Hub platform is enabling broader adoption of the technology among physiotherapy providers.
dorsaVi has also entered a commercial arrangement with Dr. Chirag Patel, an ESPN injury specialist and sports physician, to develop advanced lower limb performance metrics. These metrics are intended for use in elite sport, NCAA programs and military performance monitoring, with a specialised ViMove+ module expected to contribute to revenue opportunities from 2026.
In Europe, the company’s wearable sensors have been chosen for the SEROMA clinical research program, a large multi-site study examining axial spondyloarthritis across six medical centres. The project involves leading rheumatology researchers and collaboration with several global pharmaceutical organisations.
dorsaVi’s on-device analytics technology, which processes biomechanical data directly through its sensors, continues to support real-time insights across multiple industries. The company believes this capability may also create future opportunities in emerging fields such as robotics and advanced locomotion research.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
dorsaVi Expands Global Reach of ViMove+ Across Sport, Healthcare and Research
dorsaVi Limited (ASX: DVL) has announced further growth in the deployment of its ViMove+ motion analysis technology, with new collaborations and clinical programs supporting expansion across healthcare, elite sport and research markets.
The company’s Select Network has grown to more than 120 operational clinical sites, with additional locations currently being introduced across the United States. Integration of ViMove+ into the Select Hub platform is enabling broader adoption of the technology among physiotherapy providers.
dorsaVi has also entered a commercial arrangement with Dr. Chirag Patel, an ESPN injury specialist and sports physician, to develop advanced lower limb performance metrics. These metrics are intended for use in elite sport, NCAA programs and military performance monitoring, with a specialised ViMove+ module expected to contribute to revenue opportunities from 2026.
In Europe, the company’s wearable sensors have been chosen for the SEROMA clinical research program, a large multi-site study examining axial spondyloarthritis across six medical centres. The project involves leading rheumatology researchers and collaboration with several global pharmaceutical organisations.
dorsaVi’s on-device analytics technology, which processes biomechanical data directly through its sensors, continues to support real-time insights across multiple industries. The company believes this capability may also create future opportunities in emerging fields such as robotics and advanced locomotion research.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au